ARWR short interest
Arrowhead Pharmaceuticals Inc. · Healthcare · Biotechnology · settlement date 2026-09-30
| Shares short | 10,760,463 |
|---|---|
| Change vs prior report | 1,488,173 (+16.1%) |
| Change over six months | -17.3% |
| Days to cover | 4.03 (sector: 3.78) |
| Average daily volume | 2,669,000 |
| Rank in Healthcare | #522 of 922 by days to cover |
ARWR short interest, last 12 months
| Settlement | Shares short | Change | Days to cover | Avg daily volume |
|---|---|---|---|---|
| 2026-09-30 | 10,760,463 | +16.1% | 4.03 | 2,669,000 |
| 2026-09-15 | 9,272,290 | -1.6% | 5.15 | 1,800,675 |
| 2026-08-31 | 9,426,449 | +2.4% | 8.81 | 1,069,411 |
| 2026-08-14 | 9,207,426 | -4.7% | 7.81 | 1,178,174 |
| 2026-07-31 | 9,656,078 | +0.2% | 3.85 | 2,505,740 |
| 2026-07-15 | 9,635,297 | +14.3% | 4.86 | 1,983,559 |
| 2026-06-30 | 8,430,780 | -28.2% | 2.21 | 3,819,505 |
| 2026-06-15 | 11,738,844 | -5.3% | 8.18 | 1,434,379 |
| 2026-05-29 | 12,391,532 | -4.1% | 8.30 | 1,493,389 |
| 2026-05-15 | 12,925,632 | -0.1% | 7.01 | 1,844,498 |
| 2026-04-30 | 12,939,446 | +7.7% | 6.74 | 1,918,578 |
| 2026-04-15 | 12,012,359 | -7.6% | 7.66 | 1,567,781 |
| 2026-03-31 | 13,004,381 | +13.8% | 5.35 | 2,430,075 |
| 2026-03-13 | 11,428,679 | +2.6% | 4.31 | 2,651,024 |
| 2026-02-27 | 11,141,896 | +3.0% | 5.92 | 1,880,643 |
| 2026-02-13 | 10,818,896 | -3.0% | 2.15 | 5,023,400 |
| 2026-01-30 | 11,150,281 | +3.3% | 5.68 | 1,962,678 |
| 2026-01-15 | 10,790,834 | +12.1% | 3.00 | 3,595,445 |
| 2025-12-31 | 9,626,302 | -5.9% | 5.33 | 1,806,776 |
| 2025-12-15 | 10,234,550 | -13.5% | 2.95 | 3,466,476 |
| 2025-11-28 | 11,836,793 | +2.1% | 3.44 | 3,444,806 |
| 2025-11-14 | 11,596,104 | -1.6% | 7.11 | 1,632,052 |
| 2025-10-31 | 11,784,510 | +1.2% | 6.82 | 1,728,106 |
| 2025-10-15 | 11,648,427 | -0.4% | 6.34 | 1,837,259 |
| 2025-09-30 | 11,698,624 | -1.4% | 4.77 | 2,455,051 |
import finzdata as yf
yf.Ticker("ARWR").short_interest # every report since 2017
yf.Client().short_interest(["ARWR"], start="2018-01-01")Healthcare short interest · ARWR price history · Who owns ARWR · All short interest